Buy the full study
Summary of our market study
The French bioanalysis market is estimated at 1.5 billion euros
The global market is worth over $4.8 billion and growing at 8% per year. The COVID-19 pandemic has created new growth opportunities.
Bioanalysis dedicated to DNA testing and genomics accounts for just over a quarter of all bioanalytical activities.
In France, Eurofins Scientific holds around 75% of the French bioanalytical market.
The bioanalytical market covers environmental, food and pharmaceutical analysis.
In the environmental segment, strict regulations on pollutants and mandatory monitoring are driving the market. Companies operating in high-risk industries, public bodies and health agencies are contributing significantly to the growth in demand.
In the food industry, growing consumer concern over food safety and scandals has led to a more vigilant approach to product composition. The food products market is worth around 125 billion euros. Considerable investments have been made to guarantee food quality.
New regulations, such as the ban on certain pesticides and additives like titanium dioxide, are further boosting demand for food analysis.
In the pharmaceutical sector, safety and efficacy are at the heart of market demand. Clinical trials, safety testing and drug monitoring are an integral part of this sector.
Health scandals and counterfeiting problems are driving the need for more rigorous bioanalytical services
Players in bioanalysis
- Eurofins occupies a leading position
- Carso, strengthens the generalist segment with its solid portfolio of bioanalytical services.
- Mérieux NutriSciences, an important company in the market thanks to its testing and analysis capabilities
- SGS, Intertek and Bureau Veritas are notable participants in this field.
to understand this market
Detailed content of our market study
Inforamtion
- Number of pages : ~ 40 pages
- Format : Digital and PDF versions
- Last update :
Summary and extracts
1 Market overview
1.1 Definition and scope of the study
Bioanalysis consists of analyzing biomolecules to identify, quantify and characterize them, in order to obtain marketing authorization for a product.
The origins of bioanalysis in pharmacy stem from the emergence in Europe of drugs manufactured using biotechnologies, and corresponding to the label " Products manufactured by recombinant DNA techniques " in the European Pharmacopoeia. The methods used to analyze biomolecules are markedly different from those used for conventional analysis of relatively small organic compounds. This has given rise to a new branch of analysis: bioanalysis.
The bioanalysis market covers three sectors: healthcare, agri-food and the environment. In reality, it involves analytical subcontracting for pharmaceutical laboratories, cosmetics manufacturers, agri-food companies and others.
This is seen as a rather dynamic market, and while its average annual growth rate over the 2012-2019 period was in double digits, this has remained positive despite the health crisis. Since 2020, the Covid-19 crisis has opened up new growth prospects for this market, due to increased risk and consumers' growing mistrust of their food and pharmaceutical products.
This dynamism revolves mainly around a small number of companies that are leaders in their field: Eurofins Scientific is even the world leader in the sector. Eurofins Scientific, along with other players such as Phytocontrol and Carso, continue to expand internationally, thanks to new laboratories and acquisitions aimed at strengthening their position in the market.external growth operations aimed at reinforcing expertise already mastered by these structures or, on the contrary, helping them to develop a more complete and differentiated offer.
1.2 A highly promising global market
According to a **** study by bioanalysis group Eurofins, the global bioanalysis market is afast-growing and highly promising market , particularly in the food sector. At the time, Eurofins estimated that the global market could reach €*.* billion in value sales by ****.
More recent figures put the global bioanalysis market at US$*.* billion in ...
1.3 Sustained growth in the French market
The French market experienced sustained growth between **** and **** (***), as shown in the following graph. This increase accelerated further from ****, when the Covid-** crisis boosted the activities of bioanalytical laboratories, mainly in the food and pharmaceutical segments.
Eurofins Scientific sales France, ****-****, millions of euros Source: ****
We note that Eurofins Scientific's growth ...
1.4 Overview: PESTEL analysis
In order to gain a clear understanding of the bioanalysis market environment in France, its structural drivers and inhibitors, we propose to carry out a PESTEL analysis to determine the impact of various factors on the market.
1.5 The health crisis as a partial redefinition of the market
The bioanalytical sector is holding up rather well in the face of the health crisis, mainly thanks to the robustness of the food and pharmaceutical industries, both of which are considered essential. However, there is some uncertainty about growth in the sector in **** and ****: while it averaged +*% between **** and **** (***), it is ...
2 Demand analysis
2.1 Strong demand in all three market segments
Demand is well oriented towards the three main segments of the bioanalysis market: environmental, food and pharmaceutical analysis.
Environmental analysis
Among the main customers for bioanalytical laboratories in the environmental sector are companies (***).
One of the main factors underpinning demand in this bioanalysis segment is the evolution of regulations concerning, for ...
2.2 Traceability and transparency are becoming essential in the agri-food sector
According to a Challenges survey, **.*% of French people believe that the safety of products bought in supermarkets is declining. This is largely due to the numerous scandals that have broken out in the food industry, prompting consumers to be more vigilant about the quality and traceability of the products they ...
2.3 The credibility of the pharmaceutical market is under threat
The rise of counterfeiting in the pharmaceutical industry
Globalization, market deregulation and the free circulation of certain goods are leading to the wider distribution of counterfeit products.
According to a survey carried out for Leem (***), there has been a growing mistrust among the French, which has affected all types of medicines ...
3 Market structure
3.1 The different types of player
Segmentation *: three categories of company
There are three main types of player in the French bioanalysis market:[***] [Industrie Pharma
Generalistpure players , the three main ones being Eurofins, Carso and Mérieux NutriSciences. Eurofins has a significant market share in the healthcare segment. Diversified "follower" operators, generally specialized in one of the ...
3.2 Different growth strategies
Concentration
Bioanalytical laboratories are seeking to increase their volumes in order to reach a significant size and consequently reduce the cost of analyses, gains that are notably passed on to customers in the form of lower prices. For example, Eurofins doubled in size over the period ****-****, thanks to an acquisition ...
3.3 A market shaped by a strategy of external growth
The bioanalysis market is driven by the need to reduce costs through economies of scale, so it seems logical that the biggest players in the market are looking to make acquisitions one of the major levers of their growth.
4 Offer analysis
4.1 The main market segments and their offerings
There are three main areas of expertise for players in the bioanalysis sector in France: environment, agri-food and health.
Environmental bioanalysis
Bioanalysis in the environmental sector focuses on various components of the environment, including air quality, water quality, solids analysis and building quality.
Environmental analysis holds **% to **% of the market share ...
4.2 Prices for analysis services
An overall drop in prices
Overall, prices have fallen over the last ** years, thanks to productivity gains achieved through R&D investment.
For example, some laboratories can now carry out a toxin search in two days, at a cost of between €*** and €***, compared with €*,*** and a much longer period ** years ...
4.3 Major market trends
The market's slight loss of momentum compared to **** can be explained in several ways. Growth was partly driven by the outsourcing of certain services, but this trend is slowing down, having a direct impact on growth in the bioanalysis market.
In addition, investment in R&D has enabled bioanalytical companies to ...
5 Regulations
5.1 Current regulations
The bioanalysis market has benefited greatly from the tightening of regulations in each of the three main bioanalysis segments: sanitary controls, food controls, air and water pollutant discharges, and so on.
Pharmaceuticals and cosmetics:
Health safety in France is fundamentally based on the concept of the benefit/risk ratio: a health ...
6 Positioning the players
6.1 Segmentation
Among the main players in the bioanalysis market, there are * main generalist leaders (***), which between them account for almost **% of total market sales, and follow-on operators, the main ones being SGS, Intertek and Bureau Veritas.
m€ : billion euros m€ : million euros
- Eurofins
- Carso groupe
- Mérieux NutriSciences
- SGS
- Intertek
- Bureau Veritas BV
- Phytocontrol
- Qualtech (IFBM Groupe)
- Valbiotis
- Abbott Groupe
- Agilent Technologies
- Beckman Coulter
- Bio-Rad Laboratories
- Genomic Vision
- LFB Groupe
- Novacyt
- Qiagen
- Randox Laboratories
- Roche Diagnostics France (Roche Group)
- Thermo Fisher Diagnostics
List of charts presented in this market study
- Bioanalysis market size and forecasts
- Eurofins Scientific sales
- Pharmaceutical industry production
- Poll: "Over the last few years, would you say that the safety of products bought in supermarkets has improved...?"
- The impact of food scandals on consumer habits
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Health: Phytocontrol invests 15 million euros in a new building in Nîmes - 30/05/2024
- - Addition of 300 new employees.
- - Phytocontrol was founded in 2006, is present in six European countries and Morocco, and employs some 450 people.
- - Sales of 35 million euros in 2023, up 5% on 2022.
Inspection, certification: Bureau Veritas puts its foot on the gas pedal - 18/03/2024
- - Sales growth 2023: +8.5% (5.87 billion euros)
- - Target market share in new sectors (renewable energies, ecological transition, cybersecurity, electronic consumer goods): from 10% to 25% within 5 years
- - Acquisition of three companies specializing in the testing and certification of electrical and electronic products in Asia: cumulative sales of €20 million
- - Organic growth in Marine & Offshore by 2023: +14.4
Val-d'Oise: Bureau Veritas invests and relocates its laboratory - 22/11/2023
- Bureau Veritas in Saint-Ouen-l'Aumône for over 30 years
- The subsidiary employs 120 people
- The Bureau Veritas group employs 82,000 people worldwide, including 8,000 in France
- Bureau Veritas Group sales of 5.6 billion euros
Biomedicaments : LFB Biomanufacturing doubles its production capacity in Alès - 06/10/2023
- LFB Biomanufacturing has announced a €20 million investment in Alès, in the Gard region of France.
- LFB Biomanufacturing produces a recombinant drug from rabbit milk protein. 50% of pharmaceutical products under development are biomedicines.
- LFB Biomanufacturing has two 1,000-liter bioreactors. They plan to acquire six 2,000-liter single-use bioreactors, including two as part of this investment.
- The company plans to recruit 50 new employees by 2026, bringing its total workforce to 125.
- The LFB Biomanufacturing site, established 27 years ago, is approved by the US Food and Drug Administration.
- The LFB group, based in Les Ulis (Essonne), has sales of 524 million euros in 2022 and employs 2,600 people.
- A plant under construction in Arras (Pas-de-Calais).
Valbiotis clinically validates the first anti-diabetic dietary supplement - 17/09/2023
- Valbiotis has been developing a natural plant-based product for type 2 diabetes called Totum.63 for ten years.
- The company was founded in La Rochelle in 2014.
- Diabetes affects 537 million people worldwide, with 900 million pre-diabetics (International Diabetes Federation estimates in 2021).
- Valbiotis has invested €50 million in R&D to develop Totum.63.
- In 2020, the company signed a worldwide licensing agreement with Nestlé Health Science (NHS).
- NHS is to pay Valbiotis a lump sum of 4 million euros, bringing total payments to 7.5 million out of a potential 66 million, depending on commercial performance.
- The company is completing its study and preparing to launch its product in 2024.
- The company employs 50 people
Thermo Fisher solid despite a more difficult environment - 23/06/2023
- Thermo Fisher Scientific sales in 2022: $44.9 billion
- Thermo Fisher sales by business segment: analytical technologies (15%), specialized diagnostic products (11%), life sciences solutions (30%), laboratory products and services including CRO services (50%)
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the bioanalysis market | France
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
